Zielinski H W
Klin Monbl Augenheilkd. 1978 Dec;173(6):857-64.
Cosaldon A+E was applied in 61 patients, most of whom presented severe vascular degenerative retinochoroidal circulatory disorders and chronic glaucoma. The treatment, mostly consisting of 3--2 x 1 tablet per day, was well tolerated and resulted in marked (43 patients) and moderate (8 patients) improvement of visual function. In ten patients the symptoms remained unchanged. Particularly the improvement found in 4 patients presenting chronic glaucoma "without pressure" are worth mentioning. Besides, the symptomatology of chronic cerebrovascular insufficiency presented by most of the patients was positively influenced. Cosaldon A+E above all renders more promising the treatment of vascular processes in the eye-ground, such as the chorioretinopathy, which, in view of the unfavourable prognosis of the disease, is deemed a remarkable progress. Likewise the product seems to exert a beneficial effect in patients with chronic glaucoma.
61例患者使用了复方丹参片A+E，其中大多数患者患有严重的血管退行性视网膜脉络膜循环障碍和慢性青光眼。治疗方法主要是每天服用3-2次，每次1片，患者耐受性良好，视觉功能得到显著改善（43例）和中度改善（8例）。10例患者症状未改变。特别值得一提的是，4例“无眼压”慢性青光眼患者病情有所改善。此外，大多数患者表现出的慢性脑血管供血不足症状也受到了积极影响。复方丹参片A+E首先使眼底血管病变（如脉络膜视网膜病变）的治疗更具前景，鉴于该疾病预后不佳，这被视为一项显著进展。同样，该产品似乎对慢性青光眼患者也有有益作用。
